Vertex's Telaprevir Works In Twice Daily Dose; Response-Guided Therapy Cuts Down Drop-Outs
This article was originally published in The Pink Sheet Daily
Executive Summary
Is it a trick or a treat? AASLD lifts embargo on all annual meeting data at Halloween press conference.
You may also be interested in...
Vertex Remains On Track With Telaprevir For 2010 NDA, 2011 Anticipated Launch
Looking to be the leader in STAT-C combo therapy for hepatitis C, Vertex also plans trial testing telaprevir with VX-222.
Vertex Remains On Track With Telaprevir For 2010 NDA, 2011 Anticipated Launch
Looking to be the leader in STAT-C combo therapy for hepatitis C, Vertex also plans trial testing telaprevir with VX-222.
Boehringer Ingelheim's Phase II Agent Could Be The First Second-Wave Protease Inhibitor For Hep C
BI's '355 has impressive response rates in early studies, but jaundice is a concern.